J Korean Neurol Assoc.  1989 Dec;7(2):199-209.

Albendazole versus. Praziquantel for Therapy for Neurocysticercosis

• Jung WY
• Kim JH
• lee YJ
• park YK
• lee MS
• Choi IS

Abstract

Albendazole, one of imidazole derivatives, is an new drug for the threatment of neurocysticercosis. In this study, effectiveness of albendazole and praziquantel for therapy for parenchymal or mixed neurocysticercosis was compared. Group A included 5 patients treated with albendazole for 7-10days. Three patients among them had been treated with praziquantel previously with partial response. During treatment, all patients presented with adverse reactions, such as mild fever, intense headache, vomiting, and seizure. After 3 months of treatment, the percentage of reduction in total number and total diameter of cysts on computed tomographic scan (CT) were 55.0%, 58.0% respectively. Group B included 10 patients treated with praziquantel for 5014days. Among them, only 2 patients presented with adverse reactions. The percentage of reduction in total number and total diameter of cysts on CT were 0%, 48.1% respectively. Froup C included 5 patients treated conservatively without any specific anticysticereal agent. Follow up CT after mean of 18.6 months had shown increase in total number (125%) and total diameter (151%) of cysts. Our results indicalte that both drougs were effective for therapy for parenchymal or mixed neurocysticercosis. But, albendazole I.

MeSH Terms

Albendazole*
Fever
Follow-Up Studies
Headache
Humans
Neurocysticercosis*
Praziquantel*
Seizures
Vomiting
Albendazole
Praziquantel